PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542948
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542948
Global Wilson's Disease Treatment Market - 2024-2031
Report Overview
Global Wilson's Disease Treatment Market reached US$ 598.25 million in 2023 and is expected to reach US$ 916.91 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.
Wilson's disease is a genetic disorder caused by abnormal copper accumulation in the body. Without treatment, the disease can cause life-threatening organ damage due to the copper built up in the liver, eyes, brain, and other organs. The diagnosis of Wilson's disease is based on family history, physical exams, eye exams, blood tests, and urine tests. Liver biopsy and imaging tests may also be used.
Treatment of Wilson's disease is done with medication such as zinc. Patients who have Wilson's disease need lifelong treatment to manage symptoms to reduce or prevent organ damage. Wilson's disease can cause acute liver failure which may lead to the need for a liver transplant.
Market Dynamics: Drivers & Restraints
Increasing awareness among patients
The increasing awareness regarding Wilson's disease by various organizations and associations and its symptoms along with the growing population all over the world is expected to fuel the treatment market. Rising awareness among individuals with the campaigns and activities could lead to earlier diagnosis of Wilson's disease. This awareness could drive individuals to early diagnosis which can increase the demand for treatment options.
There is a rising concern among individuals regarding rare diseases. With the rising number of individuals with the condition, there is growing awareness among individuals. According to a publication by the American Liver Foundation in 2023, it is stated that 1 in 30,000 individuals suffer from Wilson's disease. Thus, the above factors are expected to drive the market growth.
Side effects associated with chelators
Side effects associated with chelators are severe such as bone marrow suppression and kidney complications. Other common side effects of copper chelators include weakness/tiredness, abdominal pain, loss of taste, heartburn, anorexia (lack or loss of appetite), and pale skin among others. Thus, the side effects hamper the market growth.
Market Segment Analysis
The global Wilson's disease treatment market is segmented based on medication, route of administration, distribution channel, and region.
Copper chelating medications treatment segment is expected to dominate the market share
Chelators are the first line of treatment for achieving symptomatic relief. Penicillamine and trientine are two chelating agents used to treat Wilson's disease. These medicines deplete the excessive copper levels from the body.
With high efficiency and the ability to manage the symptoms of Wilson's disease, these agents are gaining demand over the other types. Pharmaceutical companies are raising the research and development of new medications. The increasing approvals of the products could increase the segment growth.
For instance, in May 2022, Orphalan SA received the United States Food and Drug Administration (FDA) approval for Cuvrior, a new salt of trientine (trientine tetrahydrochloride). Cuvrior is approved for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine.
Market Geographical Analysis
North America is expected to hold a significant position in the Wilson's disease treatment market share
North America dominates the global Wilson's Disease Treatment market during the forecast period and it is primarily attributed to factors such as rapid growth in the geriatric population in these regions. Moreover, the established healthcare infrastructure the rising disposable income, and higher investment in R&D activities contribute to the growth of North America's share.
The rising prevalence of Wilson's disease also contributes to the growth of the market. The rising awareness among individuals regarding the diagnosis and treatment could educate individuals about the disease and available treatments. Thus, the above factors are expected to drive the region's market growth.
Market Segmentation
By Treatment
- Copper Chelating Medications
- Penicillamine
- Trientine
- Tetrathiomolybdate
- Others
- Zinc Supplements
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government Distribution Channel
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Competitive Landscape
The major global players in the market include Bausch Health Companies Inc., Teva Pharmaceutical Industries Ltd., Noblepharma Co., Ltd., Taj Pharmaceuticals Limited., Lupin Limited, Dr. Reddy's Laboratories Inc., Recordati S.p.A, Nextwell Pharmaceutical Private Limited, AstraZeneca Plc and Pfizer Inc. among others.
Why Purchase the Report?
- To visualize the global Wilson's disease treatment market segmentation based on medication, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of Wilson's disease treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global Wilson's disease treatment market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Medication
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing awareness among patients
- 4.1.2. Restraints
- 4.1.2.1. Side effects associated with chelators
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
6. By Treatment
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 6.1.2. Market Attractiveness Index, By Treatment
- 6.2. Copper Chelating Medications*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.2.3. Penicillamine
- 6.2.4. Trientine
- 6.2.5. Tetrathiomolybdate
- 6.2.6. Others
- 6.3. Zinc Supplements
- 6.4. Others
7. By Route of Administration
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Parenteral
- 7.4. Others
8. By Distribution Channel
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail Pharmacies
- 8.4. Online Pharmacies
- 8.5. Government Distribution Channel
9. By Region
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
- 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.3.1. The U.S.
- 9.2.3.2. Canada
- 9.2.3.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
- 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.4.1. Germany
- 9.3.4.2. UK
- 9.3.4.3. France
- 9.3.4.4. Italy
- 9.3.4.5. Spain
- 9.3.4.6. Rest of Europe
- 9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
- 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.4.1. Brazil
- 9.4.4.2. Argentina
- 9.4.4.3. Rest of South America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
- 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.4.1. China
- 9.5.4.2. India
- 9.5.4.3. Japan
- 9.5.4.4. South Korea
- 9.5.4.5. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
- 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
11. Company Profiles
- 11.1. Bausch Health Companies Inc.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
- 11.2. Teva Pharmaceutical Industries Ltd.
- 11.3. Noblepharma Co., Ltd.
- 11.4. Taj Pharmaceuticals Limited.
- 11.5. Lupin Limited
- 11.6. Dr. Reddy's Laboratories Inc.
- 11.7. Recordati S.p.A
- 11.8. Nextwell Pharmaceutical Private Limited
- 11.9. AstraZeneca Plc
- 11.10. Pfizer Inc. (*LIST NOT EXHAUSTIVE)
12. Appendix
- 12.1. About Us and Services
- 12.2. Contact Us
